Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q3 2023
Holdings as of Sep 30, 2023, filed Nov 14, 2023. Long positions only; changes compare share counts with Q2 2023.
- Positions
- 58
- +3 vs. Q2 2023
- Portfolio value
- $206.5M
- −$70.6M (−25.5%) vs. Q2 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 330,000 | $18.8M | 9.1% | 00.0% | Unchanged | History |
| KRYSKrystal Biotech, Inc. | COM | 80,000 | $9.28M | 4.5% | +60,000+300.0% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 57,500 | $8.40M | 4.1% | +2,500+4.5% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 1,000,000 | $8.36M | 4.0% | +175,000+21.2% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 85,000 | $7.96M | 3.9% | −15,000−15.0% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 110,000 | $7.69M | 3.7% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 664,132 | $7.60M | 3.7% | +316,700+91.2% | Added | History |
| PCVXVaxcyte, Inc. | COM | 140,000 | $7.14M | 3.5% | −140,000−50.0% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 400,000 | $7.11M | 3.4% | +250,000+166.7% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 400,000 | $6.67M | 3.2% | +175,000+77.8% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 650,000 | $6.34M | 3.1% | +75,000+13.0% | Added | History |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 525,000 | $6.04M | 2.9% | +286,775+120.4% | Added | History |
| AKROAkero Therapeutics, Inc. | COM | 115,000 | $5.82M | 2.8% | −245,000−68.1% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 130,000 | $4.99M | 2.4% | +130,000 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 40,000 | $4.85M | 2.3% | −45,000−52.9% | Reduced | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 705,881 | $4.33M | 2.1% | +424,900+151.2% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 275,000 | $4.22M | 2.0% | +35,000+14.6% | Added | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,325,000 | $4.19M | 2.0% | +1,325,000 | New | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 325,000 | $4.13M | 2.0% | +325,000 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 395,000 | $4.10M | 2.0% | +240,750+156.1% | Added | History |
| RVNCRevance Therapeutics, Inc. | COM | 350,000 | $4.01M | 1.9% | −175,000−33.3% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 215,000 | $3.94M | 1.9% | −335,000−60.9% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 98,951 | $3.38M | 1.6% | −86,049−46.5% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 101,443 | $3.02M | 1.5% | +101,443 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 200,000 | $2.90M | 1.4% | −150,000−42.9% | Reduced | History |
| IMGNImmunoGen, Inc. | COM | 175,000 | $2.78M | 1.3% | +75,000+75.0% | Added | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 55,000 | $2.77M | 1.3% | +55,000 | New | History |
| JBIOJade Biosciences, Inc. | COM | 201,197 | $2.73M | 1.3% | 00.0% | Unchanged | History |
| Morphosys AG617760202 | SPONSORED ADS | 400,000 | $2.69M | 1.3% | +400,000 | New | – |
| CYTKCytokinetics Inc | COM NEW | 90,000 | $2.65M | 1.3% | +90,000 | New | History |
| MRTXMirati Therapeutics, Inc. | COM | 60,000 | $2.61M | 1.3% | −140,000−70.0% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 325,000 | $2.60M | 1.3% | +325,000 | New | History |
| VKTXViking Therapeutics, Inc. | COM | 225,000 | $2.49M | 1.2% | −425,000−65.4% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 300,000 | $2.24M | 1.1% | −173−0.1% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 175,000 | $2.13M | 1.0% | −25,000−12.5% | Reduced | History |
| KRTXKaruna Therapeutics, Inc. | COM | 12,500 | $2.11M | 1.0% | 00.0% | Unchanged | History |
| SLRNACELYRIN, Inc. | COM | 200,000 | $2.03M | 1.0% | +200,000 | New | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 100,000 | $2.01M | 1.0% | 00.0% | Unchanged | History |
| BBIOBridgeBio Pharma, Inc. | COM | 75,000 | $1.98M | 1.0% | +33,000+78.6% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 80,000 | $1.67M | 0.8% | +80,000 | New | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 22,500 | $1.51M | 0.7% | +22,500 | New | History |
| QUREuniQure N.V. | SHS | 215,000 | $1.44M | 0.7% | 00.0% | Unchanged | History |
| RCUSArcus Biosciences, Inc. | COM | 75,000 | $1.35M | 0.7% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 150,000 | $1.34M | 0.6% | +150,000 | New | History |
| ARGXArgenx SE | SPONSORED ADR | 2,500 | $1.23M | 0.6% | +2,500 | New | History |
| VTYXVentyx Biosciences, Inc. | COM | 35,000 | $1.22M | 0.6% | +35,000 | New | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 250,000 | $1.21M | 0.6% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 100,000 | $963.0K | 0.5% | +100,000 | New | History |
| BMEABiomea Fusion, Inc. | COM | 65,000 | $894.4K | 0.4% | −125,000−65.8% | Reduced | History |
| ROIVRoivant Sciences Ltd. | SHS | 64,000 | $747.5K | 0.4% | 00.0% | Unchanged | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 45,000 | $733.5K | 0.4% | −65,000−59.1% | Reduced | History |
| INBXInhibrx Biosciences, Inc. | COM | 35,000 | $642.3K | 0.3% | 00.0% | Unchanged | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 243,287 | $632.5K | 0.3% | −169,412−41.0% | Reduced | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 150,000 | $622.5K | 0.3% | +150,000 | New | History |
| ETNB89bio, Inc. | COM | 30,000 | $463.2K | 0.2% | +30,000 | New | History |
| Avidity Biosciences, Inc.05370A108 | COM | 65,000 | $414.7K | 0.2% | 00.0% | Unchanged | – |
| Rain Oncology Inc.75082Q105 | COM | 325,000 | $280.1K | 0.1% | 00.0% | Unchanged | – |
| MRSNMersana Therapeutics, Inc. | COM | 61,250 | $77.8K | <0.1% | 00.0% | Unchanged | History |
Options (11)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | – | $21.9M |
| SRPTSarepta Therapeutics, Inc. | COM | – | $18.2M |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | $14.3M | – |
| AKROAkero Therapeutics, Inc. | COM | – | $12.6M |
| APLSApellis Pharmaceuticals, Inc. | COM | – | $7.04M |
| RCKTRocket Pharmaceuticals, Inc. | COM | – | $6.04M |
| SNDXSyndax Pharmaceuticals Inc | COM | $4.36M | – |
| REPLReplimune Group, Inc. | COM | – | $4.28M |
| CBAYCymaBay Therapeutics, Inc. | COM | – | $3.55M |
| IMVTImmunovant, Inc. | COM | $3.26M | – |
| SLRNACELYRIN, Inc. | COM | $2.03M | – |
Sold out since Q2 2023 (14)
Positions held at the end of Q2 2023 that are gone from this filing.
| Security | Class | Shares in Q2 2023 | Value in Q2 2023 | % of portfolio in Q2 2023 | History |
|---|---|---|---|---|---|
| APLSApellis Pharmaceuticals, Inc. | COM | 180,000 | $16.4M | 5.9% | History |
| RETAReata Pharmaceuticals Inc | CL A | 85,000 | $8.67M | 3.1% | History |
| INCYIncyte Corp | COM | 65,000 | $4.05M | 1.5% | History |
| ONCBeOne Medicines Ltd. | ADR | 22,500 | $4.01M | 1.4% | History |
| VIRVir Biotechnology, Inc. | COM | 150,000 | $3.68M | 1.3% | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 75,000 | $1.49M | 0.5% | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 200,000 | $1.41M | 0.5% | History |
| MORFMorphic Holding, Inc. | COM | 20,000 | $1.15M | 0.4% | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 27,578 | $723.1K | 0.3% | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 100,000 | $704.0K | 0.3% | History |
| PTCTPTC Therapeutics, Inc. | COM | 16,675 | $678.2K | 0.2% | History |
| REPLReplimune Group, Inc. | COM | 10,865 | $252.3K | 0.1% | History |
| VNDAVanda Pharmaceuticals Inc. | COM | 31,000 | $204.3K | 0.1% | History |
| KYNBKyntra Bio, Inc. | COM | 36,500 | $98.5K | <0.1% | History |